Biotech in Autoimmune/Inflammatory Disease 2004

Pharma Business Daily
Claim your FREE trial subscription!

Health Markets:

Biotech in Autoimmune/Inflammatory Disease 2004

Arrowhead Publishers
Management Report June 2004

Table of Contents

Biotech in Autoimmune/Inflammatory Disease 2004:
Revolutionizing the Market

This report assesses the role that biotechnology is playing in the field of autoimmune/inflammatory disease therapies and is focused on uncovering why
biotech drugs are proving to be the future of autoimmune disease treatment.

The value of biological drugs indicated for autoimmune diseases was roughly $6800 million in 2003. Biologics are no doubt transforming the treatment of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and psoriasis. The first biologic for the treatment of asthma was approved in 2003 and competition is increasing amongst biotech companies poised to market what will be the first new lupus drug in over thirty years.

The value of biotech in autoimmune diseases is set to triple by 2008 and this report provides information, insight, and analysis that will help industry players better understand this burgeoning market.

This report was written to provide vital analysis and information to members of the biotech, pharmaceutical, and venture capital industries and includes the following:

• Thorough financial breakdown of the leading products and companies making an impact in autoimmune disease therapy

• Market analysis and differentiation of biotech vs. synthetic drugs in combatting autoimmune diseases

• Financial forecasts for key autoimmune disease therapies as well as overall disease category value through 2008

• Integrative discussion of clinical data and key trials for already marketed and emerging biologics

• Identification and discussion of trends and issues that will have a significant impact on the future of biotech drug sales in the autoimmune market.

• Appraisal of development status for key biotech drugs being developed for various autoimmune diseases and discussion of research trends

• Up-to-date reporting on influential parterning/licensing deals in the field

For full details, please email jenniferc@cmsinfo.com

Order Form

CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Jennifer Cowlard

For more information about us, visit CMSinfo.